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We have earlier reported that anti-TAR PNA conjugated with the membrane-transducing peptide transportan inhibits transactivation of the
HIV-1 LTR resulting in decreased production of HIV-1 virions by chronically infected H9 cells (N., Kaushik, A., Basu, P., Palumbo, R.L.,
Myers, V.N., Pandey, 2002. Anti-TAR polyamide nucleotide analog conjugated with a membrane permeating peptide inhibits HIV-1
production. J. Virol. 76, 3881–3891). In this study, we have found that the PNATAR-transportan conjugate is efficiently internalized by cells
and kinetics analysis reveals a sigmoidal curve with a cooperativity index of 6, indicating very rapid cellular uptake. Additionally, analysis of
uptake at varying temperatures or in the presence of phenylarsine oxide revealed that the mechanism of uptake is neither receptor-dependent
nor occurs via endocytosis. We also found that the PNATAR-transportan conjugate exhibits potent virucidal activity as HIV-1 virions
pretreated with the conjugate were rendered noninfectious, suggesting that the conjugate may also permeate the virus envelope. The anti-
HIV-1 virucidal activity of the conjugate may be useful either in topical formulations designed to block HIV-1 infection or as a prophylactic
agent for inactivation of HIV-1 in the circulating plasma prior to attachment and entry.
D 2004 Elsevier Inc. All rights reserved.
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The major route of HIV-1 transmission from infected
individuals to non-infected individuals occurs via sexual
contacts through mucosal surfaces. Heterosexual trans-
mission accounts for a majority of infections in women
worldwide, representing a major portion of all adult
infection. The results of a 10-year study has shown that
male to female transmission rates are eight times higher than
female to male transmission rates (Padian et al., 1997). A
number of mechanisms for HIV transmission across genital
epithelia have been suggested. These include direct HIV
infection of epithelial cells, entry of HIV particles into0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.032
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E-mail address: pandey@umdnj.edu (V.N. Pandey).epithelial cells through transcytosis, transmigration of HIV-
infected epithelial cells from infected to non-infected
individuals, uptake of HIV virions by intraepithelial
Langerhans cells, and HIV entry via damaged epithelial
layers (Ibata et al., 1997; Shattock et al., 1996). Prevention
of such transmission could be blocked either through
vaccination of the non-infected population or through use
of virucidal agents that can rapidly inactivate HIV-1 virions
in the biological fluids upon contact.
Despite massive efforts during the past two decades
toward the development of an anti-HIV vaccine, an effective
vaccine is yet to be developed. Another approach for
reducing HIV transmission is the use of topical non-toxic
virucidal agents prior to sexual intercourse. A sugar binding
11 kDa protein, Cyanovirin-N produced by cyanobacterium,
was shown to be a potent virucidal agent against HIV-1 with
its virucidal activity mediated through its high-affinity05) 418–428
B. Chaubey et al. / Virology 331 (2005) 418–428 419interaction with the viral coat protein (Botos and Wlodawer,
2003). A 60-kDa cellulose acetate phthalate (CAP), a
common pharmaceutical excipient used for enteric film
coating of capsules and tablets, was shown to inactivate HIV-
1, HSV-1, HSV-2, and also non-viral pathogens which cause
sexually transmitted disease (Kawamura et al., 2000;
Manson et al., 2000). Recently, a group of tight binding
nonnucleoside RT inhibitors was also shown to exhibit
virucidal activity upon prolonged incubation with isolated
HIV-1 virions (Motakis and Parniak, 2002). Although none
of these compounds have yet reached clinical use for
combating HIV infection, a novel class of synthetic DNA
analogs, peptide nucleic acids (Nielsen, 1999; Nielsen et al.,
1991), shows great promise for this application. The antiviral
efficacy of PNAs targeted to the HIV-1 RNA genome has
been demonstrated in cell culture (Kaushik and Pandey,
2002, Kaushik et al., 2002a, 2002b; Mayhood et al., 2000).
We have recently enhanced the biodelivery characteristics
and hence, the therapeutic potential of this class of
specifically designed compounds by conjugating the anti-
HIV PNAwith a membrane transducing peptide, transportan,
a chimeric peptide derived from the sequences of the
neuropeptide galanin and wasp venom toxin mastoparan
(Langel et al., 1996; Lindgren et al., 2000). This PNATAR-
transportan conjugate inhibits HIV-1 production by chroni-
cally infected H9 cells (Kaushik et al., 2002a) when
supplemented in the culture medium. Our previous studies
have employed PNA conjugates targeted to two critical sites
within the 5VUTR (untranslated region) of the HIV-1 genome.
First, we have reported that PNA as well as PNA-DNA
chimera complementary to the primer-binding site (PBS) of
the HIV genome can completely block priming by tRNA3
Lys
(Kaushik and Pandey, 2002; Kaushik et al., 2001, Lee et al.,
1998). Secondly, we have shown that PNA targeted to
another equally important conserved region, transactivation
response region (TAR), inhibits the tat-mediated trans-
activation of the HIV-1 LTR transcription by efficient
sequestration of TAR (Kaushik et al., 2002a, 2002b;
Mayhood et al., 2000). In this communication, we demon-
strate that anti-TAR PNA conjugated with transportan
peptide is efficiently taken up by cells by a mechanism that
is not receptor-mediated or endocytotic and that preincuba-
tion with this conjugate protects cells from HIV-1 infection.
Furthermore, our results show that the conjugate exhibits
potent anti-HIV-1 virucidal activity as it is able to rapidly
permeate the virus envelope rendering the HIV-1 virions
non-infectious.Results
Cellular uptake of PNATAR-transportan conjugate
We have previously shown by fluorescence microscopy
that PNA-transportan conjugate labeled with tetramethylr-
hodamine (TAMRA) fluoroprobe is efficiently taken up bycells. A detectable fluorescence signal in the cells was
observed following incubation with 75 nM of the conjugate
for 2–12 h. However, it was unclear whether the fluores-
cence signal in the cells was dependent upon the conjugate
concentration. In order to quantitatively evaluate the uptake,
we labeled the PNATAR-transportan conjugate with fluo-
rescein and monitored the cellular uptake by FACscan. The
CEM and Jurkat cells were incubated at room temperature
with varying concentrations of fluorescein tagged conjugate
(50–500 nM) and the fluorescence signal/10,000 cells was
obtained by FACscan (Fig. 1A). The uptake of PNATAR-
transportan conjugate occurred rapidly in CEM cells and
was concentration dependent. At concentrations ranging
from 50 to 500 nM of the conjugate, a rapid increase in
fluorescence intensity displaying 20–100% fluorescence-
positive cells was observed within 30 s of incubation.
Prolonged incubation for 5 min or 1 h did not significantly
increase the fluorescence signal in CEM cells. Similar
results were obtained with Jurkat and PBMC cells as well as
with a phagocytic monocyte human cell line U-937 (Fig.
1B). The uptake in Jurkat cells was slower than that in CEM
cells at lower concentrations of the conjugate, as indicated
by a 15–20% fluorescence intensity at 100 nM concen-
tration of the conjugate (Fig. 1B). Interestingly, at concen-
trations above 100 nM, the uptake level in Jurkat cells as
judged by fluorescence intensity per 104 cells was similar to
that in CEM cells. Uptake studies with Flu-tagged uncon-
jugated PNATAR revealed no significant fluorescent inten-
sity in CEM cells even after 6 h of incubation at 10 AM
(data not shown).
The cellular uptake is neither receptor mediated nor
endocytotic
It has been shown that cellular uptake via endocytosis
is temperature-dependent and occurs at physiological
temperature (37 8C), while it is significantly reduced/
abolished at lower temperatures (Tomoda et al., 1989).
Receptor-mediated uptake has been shown to be sensitive
to phenylarsine oxide that cross-links to the thiol groups
of membrane surface proteins and blocks both endocy-
tosis and receptor function (Frost and Lane, 1985). In
order to examine whether the observed uptake of
PNATAR-transportan occurs via endocytosis or is receptor
mediated, we examined the uptake at various temperatures
followed by trypsin treatment as well as following
pretreatment of cells with phenylarsine oxide. It was
noted that the uptake of the conjugate remained
unchanged at both 4 and 37 8C (Fig. 2A). A brief
trypsin treatment of the cells following incubation with
the conjugate did not significantly alter the uptake pattern
as only 5–12% reduction in the uptake was noted at both
the temperatures (Fig. 2B). Furthermore, a 5-min pretreat-
ment of the CEM cells with 60 AM of phenylarsine
oxide, which modifies the membrane surface receptor
proteins, did not inhibit the uptake of the conjugate (Fig.
Fig. 1. (A) Uptake of PNATAR-transportan conjugate by CEM cells. Cells (2  106 cells) were incubated with varying concentrations of fluorescein-tagged
PNATAR-transportan conjugate in complete RPMI medium at room temperature. The cells were centrifuged and resuspended in fresh complete RPMI medium
and the uptake within 30 s and 5 min was evaluated by FACS analysis. (B) Comparative uptake of the conjugate in various lymphocytes.
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mediated mechanism is responsible for the uptake. We
postulate that the uptake of the conjugate may occur in a
fashion similar to the Antennapedia homeodomain peptide
penetratin (Derossi et al., 1994, 1996, 1998) via formation
of inverted micelles upon interaction of the conjugate
with the membrane bilayer. The inverted micelles are
proposed to traverse the membrane emptying their
contents into the cytoplasm.Fig. 2. Effect of temperature and phenylarsine on the cellular uptake of PNATAR-tra
concentrations of fluorescein-tagged PNATAR-transportan conjugate in complete R
washed twice with PBS solution without trypsin (Panel A) or once with PBS con
another set of experiment, cells were preincubated in the absence and presence o
centrifuged and resuspended in fresh complete RPMI medium and examined byKinetics of cellular uptake of PNATAR-transportan conjugate
In order to determine the kinetics of uptake, we
radiolabeled PNATAR-transportan conjugate with
125Iodine.
Jurkat cells (2  106) were incubated with varying
concentrations of the radiolabeled conjugate at room
temperature for 30 s followed by rapid filtration on glass
fiber filters (GF-B). The filters were washed with PBS to
remove free radiolabeled conjugate as well as conjugatensportan conjugate. CEM cells (2  106 cells) were incubated with varying
PMI medium at indicated temperatures for 30 s. The cells were centrifuged,
taining 100 Ag trypsin/ml and another wash with PBS alone (Panel B). In
f 60 AM phenylarsine oxide for 5 min at 25 8C (Panel C). The cells were
FACS analysis.
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conjugate taken up by the cells was determined by counting
the radioactivity retained on the filter by gamma counting.
Results shown in Fig. 3A illustrate the sigmoidal nature of
the uptake curve, suggesting a cooperative interaction
between the conjugate and the cellular membrane. The
[S]0.5 value and cooperativity index (ratio of [S]0.9/[S]0.1)
determined from the sigmoidal plot were 1.5 and 6 AM,
respectively (Fig. 3B). The [S]0.5 value indicates the
concentration of the conjugate at which uptake velocity is
equal to 0.5 Vmax, while the cooperativity index is the ratio
of substrate (conjugate) concentration at 0.9 Vmax and
0.1 Vmax. A Hill coefficient (nH) of 0.53 was obtained from
the slope of the Hill plot suggesting that the observed
cooperativity is not due to multiple conjugate binding sites
on the membrane.
Inhibition of HIV-1 replication
Earlier, we have shown that PNATAR-transportan con-
jugate inhibits HIV-1 production by chronically infected H9
cells when supplemented in the culture medium (Kaushik et
al., 2002a). We have further shown that the mechanism of
inhibition is at the transcription level via down regulation
of Tat-mediated transactivation of the HIV-1 LTR. In the
present study, we examined whether PNATAR-transportan
conjugate, designed primarily to inhibit the Tat-mediated
transactivation of HIV-1 transcription, is also able to block
infection of the cells by disrupting the synthesis of proviral
DNA. The CEM cells (0.5  106) were infected with
VSV-G pseudotyped HIV-1 virions at MOI of 350 in the
presence of varying concentrations of PNATAR-transportan
conjugate. Scrambled PNA-transportan (random PNA
sequence) was also included as a control. The infected
cells were pelleted, washed with PBS, and resuspended in
the fresh medium without conjugate. After 48 h of
incubation at 37 8C, the cells were harvested, lysed, and
an aliquot of each lysate containing equal amounts of
protein was assayed for firefly luciferase activity. Results
shown in Fig. 4 indicate that inhibition of luciferaseFig. 3. Uptake of 125I-labeled PNATAR-transportan conjugate by Jurkat cells. The
conjugate taken up by the cells was determined from specific radioactivity of the co
was plotted against the log of conjugate concentration and the cooperative index (
slope of the Hill plot of the uptake data shown in the left panel. Cooperative inde
coefficient (nH) represents the concentration of the conjugate at which the velociexpression was observed at all concentrations of PNATAR-
transportan conjugate. Infection of CEM cells by HIV-1
virions was performed in the presence of varying concen-
tration of conjugates. Subsequent to infection, cells were
pelleted and resuspended in the culture medium in the
absence of the conjugate. This resulted in reduced levels of
luciferase expression measured 48 h post infection.
Approximately 75–99% inhibition was noted at concen-
trations ranging from 50 nM to 2 AM of the conjugate. It
may be noted that during this period following post-
infection, inhibitor was not present in the medium and the
reduced level of luciferase expression may not be due to
inhibition of Tat mediated transactivation. This could be
due to reduced level of infection either due to inhibition of
proviral DNA synthesis upon viral entry in the cell or
inactivation of virions infectivity by disrupting the viral
membrane. These possibilities were further addressed in the
following experiments shown in Fig. 5A and B. Scrambled
PNA-transportan conjugate even at 5 AM did not exhibit
any antiviral activity.
Infectivity of HIV-1 virions pre-treated with the
PNATAR-transportan conjugate
A significant reduction of HIV-1 infection by PNATAR-
transportan conjugate as judged by reduced level of
luciferase expression in CEM cells (Fig. 4) suggests that
the conjugate may also be effective in blocking proviral
DNA synthesis, a step in the HIV-1 life cycle critical for
establishing persistent infection. The interaction of the
conjugate with the viral RNA genome may occur both in
extracellular virions and in the cytosol following fusion and
entry. To examine the first proposed interaction, HIV-1
virions were pretreated with the varying concentrations of
the PNATAR-transportan conjugate or with scrambled PNA-
transportan conjugate in complete RPMI medium and
ultracentrifuged through a 20% sucrose cushion to separate
the virion particles from the conjugate. The pre-treated
virions were then used to infect CEM cells at MOI of 350.
The infection was monitored by determining the level of125I-labeled conjugate was incubated with CEM cells and the amount of
njugate as described in Materials and methods. The uptake of the conjugate
[S]0.9/[S]0.1) was determined. Hill coefficient (nH) was determined from the
x represents the ratio of the substrate at 0.9 Vmax and 0.1 Vmax, while Hill
ty of the uptake is equal to 0.5 Vmax.
Fig. 4. (A) Dose effect curve of inhibition of viral infection/replication as a function of PNATAR-transportan conjugate. CEM cells (0.5  106 cells) were
infected with pseudo HIV virions, pNL4-3.Luc.R.E (equivalent to 14 ng p24) in the presence of varying concentrations of PNATAR-transportan or scrambled
PNA-transportan conjugate as described in Materials and methods. The infected cells were grown in complete RPMI medium at 37 8C in CO2 incubator for 48
h. Cells were harvested, lysed, and an aliquot of the lysate was assayed for luciferase activity. The percent inhibition of luciferase expression is expressed as
dEFFECTTwith respect to untreated virions (control). (B) Median effect plot and dose–response curve for the effect of PNATAR-transportan on viral replication.
The dose median for the PNATAR-transportan conjugate was determined from the dose effect curve using the CalcuSyn software (Biosoft) program. D = dose of
the PNATAR-transportan conjugate, fa = fraction of inactivation, fu = infectivity of control (untreated). Dose median for PNATAR-transportan conjugate as
estimated from the above graph is 382 nM and regression coefficient is r = 0.98 and m = 1.4. The scrambled PNA-transportan had no effect on viral infection/
replication as the levels of luciferase expression were similar to the control in the absence of PNATAR-transportan conjugate. As scrambled PNA-transportan
conjugate displayed no inhibitory effect, no value could be put in the dose effect curve plot of CalcuSyn software.
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results shown in Fig. 5 demonstrate that virion particles
pre-treated with PNATAR-transportan conjugate were
severely impaired in their ability to infect CEM cells.
Since expression of firefly luciferase is a direct conse-
quence of conversion of viral RNA into proviral DNA and
its subsequent integration into the host genome, our results
indicate that PNATAR-transportan conjugate permeates the
virion particles rendering them non-infectious while
scrambled PNA-transportan conjugate had no effect on
viral infectivity. This observation suggests that the con-
jugate is able to permeate virion particles and tightly bindFig. 5. (A) Dose effect curve of inactivation of viral infectivity following pretreatm
virions (15 ng p24) pretreated with the PNATAR-transportan conjugate were used t
cells were grown in complete RPMI medium at 37 8C in CO2 incubator for 48 h
luciferase activity. The percent inactivation of viral infectivity is expressed with r
inactivation of infectivity for HIV-1 virions pretreated with various concentrations o
was determined from the dose effect curve using the CalcuSyn software (Biosoft
inactivation, fu = infectivity of control (untreated). Dose median for PNATAR-trans
coefficient is r = 0.9243. The scrambled PNA-transportan had no effect on viral
(untreated virions). As scrambled PNA-transportan conjugate displayed no inhibit
software.to its target sequence on the viral genome. The tightly
bound conjugate would abort reverse transcription thus
preventing integration and expression of the luciferase-
encoding proviral DNA.
Uptake of the conjugate by HIV-1 virions
The loss of infectivity of HIV-1 virions pretreated with
PNATAR-transportan conjugate implies that the conjugate,
besides being rapidly taken up by the cells, may either
permeate the viral envelope which is also derived from
the cell membrane or may affect virion integrity byent of HIV-1 virions as a function of PNATAR-transportan conjugate. HIV-1
o infect the CEM cells as described in Materials and methods. The infected
. Cells were harvested, lysed and an aliquot of the lysate was assayed for
espect to the untreated virions (control). (B) Median effect plot for the log
f PNATAR-transportan. The Dose median for PNATAR-transportan conjugate
) program. D = dose of the PNATAR-transportan conjugate, fa = fraction of
portan conjugate as estimated from the above graph is 66 nM and regression
infectivity as the levels of luciferase expression were similar to the control
ory effect, no value could be put in the dose effect curve plot of CalcuSyn
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possibilities, we incubated the purified HIV-1 virions
with I125-labeled PNATAR-transportan conjugate (2  104
CPM/pmol) in complete RPMI medium for 20 min and
then ultracentrifuged through a discontinuous sucrose
density gradient. The complete RPMI medium and mock
virus sample prepared from culture supernatant of
uninfected cells were used as negative controls. Fractions
were collected from the bottom and analyzed for radio-
activity and p24 antigen levels. It was observed that a
significant portion of the radiolabeled conjugate sedi-
mented with the HIV-1 virions, as judged by the analysis
of p24 antigen peak (Fig. 6B). In contrast, the entire
radiolabeled conjugate remained at the top of the gradient
in the RPMI medium and mock virus controls (Figs. 6A
and C). These results imply that the conjugate is able to
permeate or attach to the viral envelope without disrupt-
ing the virion integrity.Fig. 6. Internalization of PNATAR-transportan in HIV-1 virions. Radio-
labeled PNATAR-transportan incubated in RPMI culture medium with or
without HIV-1 virions was ultracentrifuged through a discontinuous sucrose
density gradient. Fractions were collected from the bottom and analyzed for
radioactivity and p24 antigen. Panel A: culture medium control without
HIV-1 virion. Panel B: with HIV-1 virion. Panel C: mock virion sample
processed from uninfected cells.
Fig. 7. Abortive endogenous reverse transcription in HIV-1 virions
pretreated with PNATAR-transportan conjugate. An aliquot of HIV-1 virions
pretreated with 500 nM or 1 AM of PNATAR-transportan conjugate or
scrambled PNA-transportan conjugate were ultracentrifuged through a 20%
sucrose cushion to remove external PNA-transportan conjugate. The virion
pellet was resuspended in 0.1% NP-40 containing 10 mM DTT. An aliquot
of the disrupted virions were assayed for endogenous reverse transcription.
Lane 1, untreated HIV-1 virions; lanes 2 and 3, pre-treated with 0.5 AM and
1.0 AM of PNATAR-transportan conjugate, respectively; lanes 4 and 5, pre-
treated with scrambled PNATAR-transportan conjugate at 0.5 and 1 AM
concentrations, respectively.Pretreatment of HIV-1 virions with PNATAR-transportan
impairs endogenous reverse transcription
Following our observation that suggested the possibility
of PNATAR-transportan conjugate permeating the virion
particles, it was reasonable to infer that the conjugate may
either penetrate the nucleocapsid and bind to the TAR
region of the viral genome or may have simply attached to
the viral envelope. In the first scenario, the synthesis of
minus () strand strong stop DNA should be severely
impaired since we have earlier demonstrated that PNA
bound to the viral RNA could not be displaced by HIV-1 RT
(Lee et al., 1998). To examine this possibility, HIV-1 virions
pretreated with 500 nM or 1 AM of PNATAR-transportan
conjugate were ultracentrifuged through a 20% sucrose
cushion to remove external PNATAR-transportan conjugate.
The virion pellet was resuspended in 0.1% NP-40 contain-
ing 10 mM DTT. An aliquot of the disrupted virions were
assayed for endogenous reverse transcription. Results
shown in Fig. 7 indicate that endogenous reverse tran-
scription in HIV-1 virions pretreated with PNATAR-trans-
portan conjugate is predominantly blocked in the TAR
region (lanes 2 and 3). In the control having no conjugate or
pretreated with scrambled PNA-transportan conjugate, the
reverse transcription products were larger than 400 nucleo-
tides, which indicates that strand transfer has taken place
after the completion of the () strand strong stop DNA
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that the conjugate permeates the virions and binds to the
TAR region of the viral RNA, it is also possible that the
conjugate may have tightly attached to the viral envelope
externally and may have bound to the target only after the
virion was disrupted. However, the FACScan analysis in
which cells treated with trypsin to degrade the PNA
conjugate revealed a similar pattern of conjugate uptake to
untreated cells, suggesting that uptake by virions having cell
membrane-derived envelope would likely occur by a similar
mechanism. Regardless of the mechanism, the infectivity of
the virion particles is significantly impaired indicating the
potential of this class of compounds as virucidal agents
against HIV-1.Discussion
A number of potential drug candidates fail because of
associated cellular uptake problems. This problem is often
addressed by optimizing their biophysical properties to
enhance cellular uptake to acceptable levels. The therapeutic
potential of PNAs as gene-specific, nontoxic, non-immuno-
genic compounds has been limited due to their poor cellular
uptake (Derossi et al., 1998). We have used a highly
effective strategy to overcome this obstacle and improve
their biodelivery by conjugating the PNAwith a membrane-
transducing peptide, transportan, a chimeric peptide derived
from the neuropeptide galanin and wasp venom toxin
mastoparan (Langel et al., 1996; Lindgren et al., 2000).
Using PNATAR-transportan targeting the TAR region of the
HIV-1 genome as the model conjugate, we observed that it
is efficiently taken up by cells. Unlike other membrane
transducing peptides such as those derived from HIV-1 Tat
protein (Fawell et al., 1994; Frankel and Pabo, 1988;
Schwarze and Dowdy, 1999; Silhol et al., 2002) or HSV
VP22 (Dilber et al., 1999; Elliott and O’Hare, 1997, 1999;
Phelan et al., 1998), which are highly basic, transportan is
comparatively hydrophobic in character containing only
four lysine residues. The cellular uptake of this peptide
alone has been shown to be nonsaturable and resistant to
treatment with phenylarsine oxide or hyperosmolar sucrose
solution, suggesting that the mechanism of uptake is not
endocytotic- or receptor-mediated (Pooga et al., 1998).
Similar results were obtained with PNATAR-transportan
conjugate except that the uptake shows a sigmoidal curve
indicating cooperative interaction between the cellular
membrane and the conjugate. The observed cooperativity
of uptake may be due to micelle formation, which requires a
concentration threshold of components. A cooperativity
index of 6 suggests that in order to increase the uptake
velocity from 0.1 to 0.9 Vmax, only 6-fold increase in the
concentration of conjugate is required. Any drug/compound
displaying a sigmoidal pattern of uptake kinetics is expected
to be more effective than that displaying a hyperbolic
pattern since theoretically the latter would require a 90-foldincrease in the substrate concentration to achieve an uptake
velocity of 0.9 Vmax from 0.1 Vmax. We have earlier shown
that supplementing PNATAR-transportan conjugate in the
culture medium significantly inhibited HIV-1 production by
chronically infected H9 cells (Kaushik et al., 2002a). This
inhibition of virus production was shown to be due to down
regulation of Tat-mediated transactivation of HIV-1 tran-
scription. In the present study, we found that infection of
CEM cells by HIV-1 virions was also drastically reduced in
the presence of PNATAR-transportan conjugate. This result
was surprising since PNA targeting the TAR region of the
viral genome was predicted to function at the transcriptional
level after infection has taken place. The PNATAR-trans-
portan conjugate may also interfere with the synthesis of
proviral DNA, a crucial step for establishing the viral
infection. We made this inference following our observation
that infectivity of HIV-1 virions was drastically reduced
when pretreated with PNATAR-transportan conjugate. The
EC50 was found to be as low as 50 nM. These results
suggest that the conjugate may either permeate the virus
envelope and bind to its target sequence on the viral genome
or alternatively it may affect viral entry by binding to viral
membrane and disrupting its integrity. If the first scenario
holds true, when pretreated virions enter the cell, reverse
transcription is likely to be aborted in the TAR region since
the PNA conjugate bound to the TAR region cannot be
displaced by reverse transcriptase. The fact that the radio-
iodinated PNATAR-transportan conjugate co-sediments
along with virion particles in discontinuous sucrose density
gradient suggest that conjugate may have been taken up by
the virion particles or strongly attached to the viral
membrane. When such virions were separated from the free
conjugate and examined for endogenous reverse transcrip-
tion activity, all reverse transcription products were found to
be aborted exclusively in the TAR region.
The PNATAR-transportan conjugate contains potential
anti-HIV virucidal activity which is able to inactivate
virions before they can infect healthy cells. Currently
available drugs targeting viral RT and protease operate by
inhibiting replication of HIV only after it has infected target
cells. Entry inhibitors have recently been shown to block
HIV entry into cells but do not inactivate virions circulating
in the plasma (Derdeyn et al., 2000; Nagashima et al., 2001;
Wild et al., 1993). Our approach is unique in the sense that
HIV-1 virions in the plasma may be rapidly inactivated prior
to their entry into cells upon exposure to PNA conjugates
targeting critical regions of the HIV-1 genome. Future
development of PNA technology may continue to improve
biodelivery of these antisense agents which, due to their
resistance to degradation by nucleases, have great advan-
tages over other antisense molecules. In addition to their
potential value as therapeutic agents, these conjugates may
also have great potential as prophylactic agents to block
HIV-1 infection following accidental exposure to the virus
or as virucidal agents used to prevent infection during
sexual contact.
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PNA oligomers
The anti-TAR PNA was synthesized and fluorenyl
methoxycarbonyl cysteine (Fmoc-Cys) was coupled directly
to the PNA at the N-terminal. For fluorescein labeling,
Fmoc-O-Cys PNA was synthesized with dOT spacer known
as egl linker at the N-terminus while for 125I radiolabeling, a
Tyr residue was placed at the C-terminus. All the PNA
samples were purified on C18 reverse phase HPLC columns
which was pre-equilibrated with solvent A (0.1% TFA in
water) at 45 8C. The elution profile was developed by
increasing the concentration of solvent B (0.1% TFA in
100% acetonitrile) as follows: 0–5 min (0% B), 5–50 min
(60% B).
Fluorescein labeling of PNA
The Fmoc-O-Cys-PNA targeting TAR region of HIV-1
genome was labeled with fluorescein while still immobi-
lized on the resin. The Fmoc group protecting the amino
group was removed by treating with 1 ml of 20% piperidine
in dimethyl formamide (DMF) for 5 min followed by
washing the column with equal volume of DMF three times.
The 5-carboxy fluorescein succinimidyl ester (5 mg)
dissolved in 325 AL of DMF containing 7.5% diisopropyl
ethylamine (v/v) and added to the resin. The labeling
reaction was carried out at room temperature for 1 h with
occasional shaking by moving the solution back and forth
using two syringes attached at each end of the column. The
reaction was stopped by flushing out the labeling solution
from the column followed by washing the resin three times
with DMF and with DCM (1 ml each washing). The resin
was treated with 100 Al of deprotecting solution containing
10% TFA and 2% m-cresol (v/v) in DCM to remove the
trityl group from the terminal cysteine and Bhoc (benzhy-
drylcarbonyl) group from PNA. After 5 min, the deprotect-
ing solution was replaced with the fresh one and further
incubated for 5 min. The resin was then treated with 250 Al
of TFA/m-cresol (4:1 v/v) at room temperature for 2 h to
release the PNA. The TFA/m-cresol solution containing
PNAwas collected and the resin was washed twice with 100
Al of TFA. The fluoresceinated PNA was precipitated by 5-
fold excess of dry cold ether followed by incubation on dry
ice for 10 min. The precipitate was collected by centrifu-
gation at 5,000 rpm for 5 min. The precipitate was washed
once with the cold dry ether and air-dried. The fluorescein-
labeled PNA was quantified spectrophotometrically by
measuring the absorbance of a diluted sample at 260 and
490 nm.
Synthesis of PNA-transportan conjugate
All the solvents used were degassed prior to use by
bubbling with helium gas for 10 min. PNA (1 Amol, 1 eq.)was dissolved in NMP (N-methyl pyrrolidinone)-H2O (1:1,
v/v) to a final concentration of 1 mM. The NPYS-peptide
(1.3 eq) dissolved in NMP with a final concentration of 10
mM was added to the PNA solution. The solution was
supplemented with 100 eq. of 1 M sodium acetate buffer (pH
5.0), mixed by vortexing and incubated at 40 8C. After 3 h of
incubation, the coupling reaction was quenched by addition
of 5% TFA to a final conc. 650 mM. The purification of the
conjugate was carried out by HPLC on YMC guardpak
ODS-AQ C18 column (S-3 Am, 12 nm, 4  50 mm) using
water: acetonitrile gradient (containing 0.5% acetic acid v/v)
with column temperature maintained at 45 8C. The desired
fractions were lyophilized and stored at 20 8C. Quantita-
tion of the PNA-transportan conjugate was carried out by
measuring absorbance at 260 nm and the OD value was
divided by the molar extinction coefficient. Mass spectrom-
etry of the conjugate was performed on a Perspective
Biosystems Voyager DE MALDI-TOF system using sina-
pinic acid matrix.
Proviral clones and Plasmid
An env () HIV-1 proviral clone, pNL4-3.Luc.R.E.,
encoding a luciferase reporter gene, was obtained from the
NIH-AIDS Reference and Reagent Program, while pVSV-G
plasmid expressing the G glycoprotein of vesicular stoma-
titis virus was purchased from CLONETECH.
Production of HIV-1 virions
The 293T cells were transfected with 10 Ag of pNL4-
3.Luc.R.E and 10 Ag of pVSV-G DNA (Akkina et al., 1996)
by calcium phosphate method (Chen and Okayama, 1987)
and grown in Dulbecco’s modified Eagle’s medium
supplemented with FCS (10%) and antibiotics. After 12 h,
the transfected cells were washed with PBS and grown for
another 48 h in complete medium. The culture supernatant
was collected and passed through 0.45 Am cellulose acetate
filters. The p24 antigen level in the filtered supernatant was
determined by ELISA. The viral stock was aliquoted and
stored at 80 8C.
Purification of HIV-1 virions
The filtered culture supernatant (500 ml) containing HIV-
1 virions was centrifuged at 70,000  g for 45 min. The
virion pellet was resuspended in 2 ml of PBS and
recentrifuged through 5 ml of 20% sucrose/PBS cushion
for 30 min at 100,000  g. The virion pellet was
resuspended in complete Dulbecco’s medium and stored at
80 8C.
Preparation of subtilisin-treated HIV-1 virions
Purified HIV-1 virion preparations have been shown to
be contaminated with cellular microvesicles of 50–500 nm
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these microvesicles, viral pellets were resuspended in 500
AL of Dulbecco’s phosphate buffered saline containing 1
mM CaCl2 and treated with subtilisin (1 mg/ml) at 37 8C for
18 h (Ott et al., 1996). The subtilisin digestion was stopped
by PMSF (5 Ag/ml) and virion particles were centrifuged
through 1 ml of 20% sucrose. The virion pellet was
resuspended in Dulbecco’s phosphate-buffered saline with-
out CaCl2 or MgCl2.
Determination of HIV-1 virion number in the purified
sample
HIV-1 virions were quantified by determination of the
RNA copy number in the sample using Nuclesins HIV-1-QT
Amplication Kit (Organon Teknika, Durham, NC). The
virion number was also determined from the p24 concen-
tration, as excellent correlation between HIV-1 RNA copy
number and p24 concentration has been demonstrated (Vass,
2002). Considering that 2000 copies of p24 are present per
virion particle, the virion number estimated from the RNA
copy number were in agreement with the number deter-
mined by p24 quantification (1 pg p24/12500 virions).
FACscan analysis of cellular uptake
CEM and Jurkat cells grown in complete RPMI 1640
medium containing 10% FCS were harvested, washed with
PBS and resuspended in the same medium at a cell density
of 4  106 cells/ml. Cells were aliquoted in 12-well
microtiter plate at 2  106 cells per well and incubated at
room temperature with varying concentrations of fluores-
cein tagged PNATAR-transportan conjugate (50–500 nM). At
varying time points, the cells were centrifuged and
resuspended in the same medium without the conjugate
and fluorescent signal/10,000 cells were obtained by
FACscan.
Uptake kinetics
The PNATAR-transportan conjugate was labeled with
125I
using the radioisotope and the chloramine-T labeling kit
from ICN. For radiolabeling, 0.5 nmol of the conjugate and
0.28 nmol of 125-I (0.5 mCi) were reacted in the presence of
2.8 nmol of chloramine-T for 1 min according to the
manufacturer’s protocol and quenched by the addition of 62
nmol of sodium metabisulfite. The labeled conjugate was
purified by NAP-10 gel filtration (Amersham), followed by
C18 disposable cartridges. The final purified product was
lyophilized, dissolved in water, and quantified by absorption
at 260 nm. The specific radioactivity was adjusted to desired
concentration by adding unlabeled conjugate. For uptake
experiments, 2  106 Jurkat cells were incubated with
varying concentrations of the radiolabeled conjugate at
room temperature. Following a 30-s incubation, each
individual sample was filtered on glass fiber filter (GF-B),washed extensively with phosphate buffered saline solution
and the amount of radiolabel internalized into the cells was
determined by gamma counting. The [S]0.9/[S]0.1 ratio
(cooperativity index) of the substrate at 0.9 Vmax and 0.1
Vmax was determined by plotting the uptake versus substrate
concentration. Hill coefficient (nH) was determined from
the Hill plot of uptake data.
Uptake of PNATAR-transportan conjugate by virion particles
The purified HIV-1 virion particles were incubated with
50 nM of I125-labeled PNATAR-transportan conjugate (1.8 
105 CPM/pmol) in complete RPMI medium (250 Al) for 20
min. The RPMI medium and mock-virus sample served as
negative controls. The incubation mixture was then sub-
jected to ultracentrifugation through a discontinuous sucrose
density gradient (1 ml of 40% sucrose/PBS + 2 mL of 20%
sucrose/PBS + 2 ml of 10% sucrose/PBS) for 1 h. Fractions
were collected from the bottom and analyzed for p24 and
presence of radioactivity.
Infectivity of HIV-1 virions pre-treated with
PNATAR-transportan conjugate
The HIV-1 virions (equivalent to 15 ng p24) containing
firefly luciferase reporter were incubated with varying
concentrations of PNATAR-transportan conjugate for 1 h in
complete RPMI medium in a final volume of 250 Al.
Control experiments without the conjugate or with
scrambled PNA-transportan conjugate were also performed
simultaneously. The virion particles were separated from the
conjugate by centrifuging through a 20% sucrose/PBS
cushion for 30 min at 100,000  g and the virion pellets
were resuspended in 500 Al of complete RPMI medium.
Infection was performed by incubating the pretreated virions
with CEM cells (0.5  106 cells) at 37 8C for 2 h in a final
volume of 1.0 ml RPMI medium containing 10 Ag/ml
polybrene. Infected CEM cells were washed with PBS and
resuspended in 1 ml of complete RPMI medium and
incubated in a 37 8C, CO2 incubator. After 48 h, cells were
harvested, washed and lysed in 250 Al of Passive Lysis
Buffer (Luciferase assay kit, Promega) for 15 min on a
rocking shaker. The lysates were centrifuged at 13,000 rpm
for 10 min and the supernatants were collected. An aliquot
of each supernatant containing equivalent protein was
analyzed for firefly luciferase activity in a 96-well fluorotrac
plate using a Packard Top Count Luminescent counter as
described before (Nadal et al., 1999).
Endogenous reverse transcription in HIV-1 virions
pretreated with PNATAR-transportan
HIV-1 virions (5  1011/mL) were incubated with 0.5–
1.0 AM concentrations of PNATAR-transportan or scrambled
PNA-transportan in complete RPMI medium (200 Al) for 30
min at 4 8C. The incubation mixture was then layered on 3
B. Chaubey et al. / Virology 331 (2005) 418–428 427ml of 20% sucrose and centrifuged at 100,000  g for 30
min. The virions pellet free from external PNATAR-trans-
portan conjugate was resuspended in Tris buffer containing
0.1% NP-40 and 10 mM DTT to disrupt the viral
membrane. An aliquot of the disrupted virions was
examined for endogenous RT activity by supplementing
with 2 mM MgCl2 and 5 AM of each dNTPs containing 5
ACi each of [a-32P]dCTP and [a-32P]dATP. Following 1-h
reaction at 37 8C, the mixture was extracted with phenol-
chloroform, precipitated with alcohol and lyophilized. The
lyophilized material was dissolved in TE buffer and
resolved on denaturing polyacrylamide-urea gel.Acknowledgment
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